Mason Archival Repository Service

A Study of the Humanized Monoclonal Antibody CT109 in Combination with FOLFIRI and Bortezomib as a Treatment for Colorectal Cancer

Show simple item record

dc.contributor.author Arias Cardenas, Kelly
dc.creator Arias Cardenas, Kelly
dc.date 2019-12-03
dc.date.accessioned 2020-06-02T17:09:01Z
dc.date.available 2020-06-02T17:09:01Z
dc.identifier.uri http://hdl.handle.net/1920/11788
dc.description.abstract Colorectal cancer ranks as the 2nd leading cause of cancer death in the United States. New drugs are urgently needed to increase the survival of patients with colorectal cancer. FOLFIRI is the most commonly used chemotherapy treatment in colorectal cancer, yet most patients develop side effects that severely affect quality of life. Bortezomib, an anti-cancer drug approved for multiple myeloma and lymphoma has been reported as an effective treatment in colorectal cancer that enhances apoptosis and attenuates tumor growth. Stromatis Pharma has developed a humanized monoclonal antibody, CT109, against CEACAM6 (new checkpoint inhibitor) that has demonstrated its promising antitumor activity against pancreatic and colorectal cancer in preclinical models. Monoclonal antibodies (moAbs) can be used in combination with drugs to treat cancer as adjunct therapy. MoAbs minimize treatment toxicity and are more effective at shrinking xi tumors, inhibiting tumor growth, prolonging life, and/or improving quality of life. The purpose of this study was to evaluate the functional capabilities of CT109 either alone or in combination with chemotherapy treatments. We used antibody-dependent cellular cytotoxicity (ADCC) assays, immunoblotting and cell viability assays as an in-vitro assessment of the CT109 efficacy in combination with chemotherapy drugs. Results show that the combination of CT109 with Bortezomib enhanced poly ADP ribose polymerase (PARP) cleavage and increased apoptosis in HT29 cells. Further, the synergistic inhibition and/or reduction of tumor growth, in combination with FOLFIRI, were observed in-vivo, in a colorectal adenocarcinoma tumor xenograft model in nu/nu mice. We found that the humanized monoclonal antibody CT109 enhanced the anti-cancer effect of both treatments. These data support the use of a novel monoclonal antibody, CT109 as an adjunct therapy to treat this deadly malignancy. en_US
dc.language.iso en en_US
dc.subject FOLFIRI en_US
dc.subject colorectal en_US
dc.subject cancer en_US
dc.subject Bortezomib en_US
dc.title A Study of the Humanized Monoclonal Antibody CT109 in Combination with FOLFIRI and Bortezomib as a Treatment for Colorectal Cancer en_US
dc.type Thesis en_US
thesis.degree.name Master of Science in Biology en_US
thesis.degree.level Master's en_US
thesis.degree.discipline Biology en_US
thesis.degree.grantor George Mason University en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search MARS


Browse

My Account

Statistics